Quick Answer
CNBX Pharmaceuticals Inc. reported Stockholders Equity of -$2.50 million for the year ending 2025.
- CNBX Pharmaceuticals Inc. showed a decrease of -0.7% in Stockholders Equity from 2024 to 2025.
- This data is from CNBX Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on December 1, 2025.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: -$105.4 thousand | Q4 2013: -$18.7 thousand | Q1 2014: -$49.9 thousand | Q2 2014: -$3.8 thousand | Q4 2014: $4.42 million | Q1 2015: $4.39 million | Q2 2015: $4.24 million | Q4 2015: $157.3 thousand | Q1 2016: -$398.2 thousand | Q2 2016: -$398.9 thousand | Q4 2016: -$230.5 thousand | Q1 2017: -$177.9 thousand | Q2 2017: $2.88 million | Q4 2017: $2.42 million | Q1 2018: $3.25 million | Q2 2018: $2.64 million | Q4 2018: $9.07 million | Q1 2019: $17.97 million | Q2 2019: $19.32 million | Q4 2019: $6.06 million | Q1 2020: $3.12 million | Q2 2020: $2.51 million | Q4 2020: $1.26 million | Q1 2021: $3.78 million | Q2 2021: $2.33 million | Q4 2021: $802.7 thousand | Q1 2022: -$648.0 thousand | Q2 2022: -$1.18 million | Q4 2022: -$1.97 million | Q1 2023: -$2.01 million | Q2 2023: -$1.91 million | Q4 2023: -$2.09 million | Q1 2024: -$2.36 million | Q2 2024: -$2.45 million | Q3 2024: -$2.48 million | Q4 2024: -$2.51 million | Q1 2025: -$2.57 million | Q2 2025: -$2.54 million | Q3 2025: -$2.50 million | Q4 2025: -$2.57 million.
- Over the full 18 years of available data (2008 to 2025), CNBX Pharmaceuticals Inc.'s Stockholders Equity has declined by 961.2%.
- Historical annual values: Fiscal year 2025: -$2.50 million | Fiscal year 2024: -$2.48 million | Fiscal year 2023: -$2.02 million | Fiscal year 2022: $1.63 million | Fiscal year 2021: $1.81 million | Fiscal year 2020: $1.76 million | Fiscal year 2019: $14.74 million | Fiscal year 2018: $2.65 million | Fiscal year 2017: -$2.94 million | Fiscal year 2016: -$467.4 thousand | Fiscal year 2015: -$309.6 thousand | Fiscal year 2014: $40.1 thousand | Fiscal year 2013: -$105.4 thousand | Fiscal year 2012: -$49.0 thousand | Fiscal year 2011: -$47.3 thousand | Fiscal year 2010: $60.0 thousand | Fiscal year 2009: $175.0 thousand | Fiscal year 2008: $289.9 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: